Panobinostat (Standard)

CAT:
804-HY-10224R-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Panobinostat (Standard) - image 1

Panobinostat (Standard)

  • Description:

    Panobinostat (Standard) (LBH589 (Standard) ) is the analytical standard of Panobinostat (HY-10224) . This product is intended for research and analytical applications. Panobinostat is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].
  • Product Name Alternative:

    LBH589 (Standard) ; NVP-LBH589 (Standard)
  • UNSPSC:

    12352005
  • Hazard Statement:

    H301+H331, H315, H318, H360, H373
  • Target:

    Apoptosis; Autophagy; HDAC; HIV; Reference Standards
  • Related Pathways:

    Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Others
  • Applications:

    COVID-19-anti-virus
  • Field of Research:

    Cancer; Infection
  • Purity:

    98.09
  • Smiles:

    ONC(/C=C/C(C=C1)=CC=C1CNCCC2=C(C)NC3=CC=CC=C23)=O
  • Molecular Formula:

    C21H23N3O2
  • Molecular Weight:

    349.43
  • Precautions:

    H301+H331, H315, H318, H360, H373
  • References & Citations:

    [1]Scuto A, et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood. 2008 May 15;111 (10) :5093-100.|[2]Crisanti MC, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 2009 Aug;8 (8) :2221-31. |[3]Ocio EM, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010 May;95 (5) :794-803.|[4]Barton K, et al. Broad activation of latent HIV-1 in vivo. Nat Commun. 2016;7:12731. Published 2016 Sep 8.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    4°C, sealed storage, away from light and moisture
  • Scientific Category:

    Reference Standards
  • Clinical Information:

    No Development Reported
  • CAS Number:

    [404950-80-7]